Drugs / TLC-3595
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05665751 | Mar 2023 → Sep 2024 overdue | — | OrsoBio, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-21 | OrsoBio, Inc | Results OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84th Scientific Sessions orsobio.com ↗ |
| 2022-11-03 | OrsoBio, Inc | Results OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders orsobio.com ↗
TLC-3595 treatment led to improvements in LDL and total cholesterol, confirming the compound’s pharmacodynamic effects, and its pharmacokinetic properties support once daily oral administration. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC-3595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05665751 ↗ |
| Route | Oral | “Tablets administered orally” NCT05665751 ↗ |